Obesity Management Medications as Adjuncts to Metabolic and Bariatric Surgery: Consensus Recommendations from India
- PMID: 40392474
- DOI: 10.1007/s11695-025-07895-5
Obesity Management Medications as Adjuncts to Metabolic and Bariatric Surgery: Consensus Recommendations from India
Abstract
Obesity is a global health concern, with weight regain (WR) common after bariatric surgery. Clear guidelines on post-surgical medication use are essential. This expert consensus evaluates the role of obesity management medications (OMMs) in optimizing weight loss (WL) and preventing WR in individuals undergoing metabolic and bariatric surgery (MBS). Using a modified Delphi approach, a panel of 12 experts reviewed evidence and formulated consensus recommendations. Two voting rounds led to consensus on 11 of 15 statements, covering preoperative WL strategies and postoperative weight management. The recommendations guide OMM selection, timing, and effectiveness in enhancing WL outcomes. Integrating OMMs into bariatric care protocols can help clinicians improve long-term success rates in obesity management.
Keywords: Bariatric surgery; Metabolic surgery; Obesity management; Overweight; Weight loss.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics Approval and Consent to Participate: This article does not contain any studies with human participants or animals performed by any of the authors. Competing interests: RG received speaker's honorarium from Novo Nordisk and Eli Lilly pharmaceutical companies. However, no financial transaction is related to the current manuscript or has an impact on the content of this manuscript. ND, RW, AK, Shashank S declare no conflict of interest. AGB received honorarium for lectures/presentations from Novo Nordisk. AMN, DG, RP, SB, Manish K, SA declare no conflict of interest. AA, AB, GS, JSA, JLXL, JP, KPP, KSK, MN, Mandeep K, MM, RB, RKS, SC, SP, Sumeet S, SU, SJJ, VS declare no conflict of interest.
References
-
- Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221–62 Published correction in: Lancet Diabetes Endocrinol. 2025;13(3):e6. - PubMed
-
- Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474–89. - PubMed
-
- Ray S, Kapoor N, Deshpande N, Chatterjee S, Kumar J, Tantia O, et al. An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update. Expert Rev Clin Pharmacol. 2024;17(4):349–62. - PubMed
-
- Deshpande NR, Kapoor N, Dalal JJ, Palshetkar N, Shah S, Makkar BM, et al. Consensus on current landscape and treatment trends of obesity in India for primary care physicians. J Assoc Physicians India. 2023;71(10):69–77. - PubMed
-
- Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg. 2014;24(3):437–55. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
